{"id":4412,"date":"2019-03-12T14:41:57","date_gmt":"2019-03-12T09:11:57","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4412"},"modified":"2023-06-14T16:22:33","modified_gmt":"2023-06-14T10:52:33","slug":"notizia-breast-cancer","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer","title":{"rendered":"Notizia"},"content":{"rendered":"\n<p><strong>Stemline gives in-licenses global rights to SL-1001<\/strong><\/p>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\"><strong>Stemline Therapeutics,<\/strong> Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule <strong>RET (rearranged during transfection) kinase inhibitor.<\/strong> The<strong> RET kinase genetic mutations<\/strong> are found in a wide range of <a href=\"https:\/\/www.delveinsight.com\/report-store\/medullary-thyroid-cancer-market\">cancers<\/a> and are prime targets in most of them. The Compound-<strong> SL-1001<\/strong>, designed by the scientists at Cancer Research UK Manchester Institute at the<strong> University of Manchester<\/strong> (United Kingdom), has shown its potential in targeting the RET molecule showing its anti-cancer nature. <\/p>\n\n\n\n<p><strong>HIV injectable treatment\na huge relief to patients <\/strong><\/p>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\">In a very first, an injectable drug for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hiv-associated-lipodystrophy-market\">HIV<\/a><\/strong> proves to be as effective as the pills. The injection suppressed the Virus expression over 90% in an effective manner. It will also provide relief to patients from taking regular oral pills. The Phase III trials conducted by <strong>Viiv Healthcare<\/strong> in association with<strong> Johnson &amp; Johnson\u2019s Edurant. <\/strong><\/p>\n\n\n\n<p><strong>FDA approves a biosimilar\nto HERCEPTIN<\/strong><\/p>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\">The U.S <strong>Food and Drug Administration<\/strong> has approved <strong>Pfizer\u2019s<\/strong> biosimilar to <strong>Roche<\/strong>\u2019s <strong>Herceptin <\/strong>for Breast Cancer treatment. Earlier, <strong>Herzuma manufactured by <\/strong>South Korean manufacturer <strong>Cellitrion<\/strong> and Israel\u2019s <strong>Teva pharmaceutical industries<\/strong>, got FDA\u2019s approval as well. &nbsp;<\/p>\n\n\n\n<p><strong>Specific kind of\nelectrical brain stimulation to treat Depression <\/strong><\/p>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\"><strong>UNC School of Medicine researchers<\/strong> in their recent experiment showed with the help of weak alternating electrical current passed via electrodes can help stimulate Brain signals thus targeting <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/bipolar-disorder-manic-depression-market\">Depression<\/a><\/strong>. Over 70% of people subjected <strong>Transcranial alternating current stimulation (tACS) <\/strong>reported a 50% reduction in depression symptoms. <\/p>\n\n\n\n<p><strong>An OK to Roche\u2019s\nImmunotherapy for TNBC by FDA<\/strong><\/p>\n\n\n\n<p class=\"has-very-light-gray-background-color has-background\">FDA approved <strong>Roche\u2019<\/strong>s first immunotherapy to target <strong>metastatic breast cancer<\/strong>.<strong> Tecentriq <\/strong>in combination with older chemotherapy called<strong> Abraxane<\/strong> will benefit patients affected with <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/triple-negative-breast-cancer-tnbc-market-insight\" class=\"ek-link\">triple-negative breast cancer (TNBC)<\/a><\/strong>. However, the approval is further subjected to confirm the positive results. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stemline gives in-licenses global rights to SL-1001 Stemline Therapeutics, Inc. is a biopharmaceutical company focused on development and commercialization of novel oncology therapeutics, has licensed worldwide rights to a preclinical molecule RET (rearranged during transfection) kinase inhibitor. The RET kinase genetic mutations are found in a wide range of cancers and are prime targets in [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4418,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[631,127,137,704,292,297,460,524,2784],"industry":[17225],"therapeutic_areas":[17229,17227,17228],"class_list":["post-4412","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biosimilar","tag-breast-cancer","tag-cancer","tag-fda","tag-herceptin","tag-hiv","tag-pfizer","tag-roche","tag-stemline","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia 12\/03\/2019 - DelveInsight Business Research LLP<\/title>\n<meta name=\"description\" content=\"FDA approved Roche\u2019s first immunotherapy to target metastatic breast cancer. Tecentriq in combination with older chemotherapy called Abraxane...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia 12\/03\/2019 - DelveInsight Business Research LLP\" \/>\n<meta property=\"og:description\" content=\"FDA approved Roche\u2019s first immunotherapy to target metastatic breast cancer. Tecentriq in combination with older chemotherapy called Abraxane...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-12T09:11:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T10:52:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/10022133\/Capture20-4.png\" \/>\n\t<meta property=\"og:image:width\" content=\"547\" \/>\n\t<meta property=\"og:image:height\" content=\"424\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia 12\/03\/2019 - DelveInsight Business Research LLP","description":"FDA approved Roche\u2019s first immunotherapy to target metastatic breast cancer. Tecentriq in combination with older chemotherapy called Abraxane...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer","og_locale":"en_US","og_type":"article","og_title":"Notizia 12\/03\/2019 - DelveInsight Business Research LLP","og_description":"FDA approved Roche\u2019s first immunotherapy to target metastatic breast cancer. Tecentriq in combination with older chemotherapy called Abraxane...","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-03-12T09:11:57+00:00","article_modified_time":"2023-06-14T10:52:33+00:00","og_image":[{"width":547,"height":424,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/10022133\/Capture20-4.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer","url":"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer","name":"Notizia 12\/03\/2019 - DelveInsight Business Research LLP","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/10022133\/Capture20-4.png","datePublished":"2019-03-12T09:11:57+00:00","dateModified":"2023-06-14T10:52:33+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"FDA approved Roche\u2019s first immunotherapy to target metastatic breast cancer. Tecentriq in combination with older chemotherapy called Abraxane...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-breast-cancer#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/10022133\/Capture20-4.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/10022133\/Capture20-4.png","width":547,"height":424},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/03\/10022133\/Capture20-4-300x233.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biosimilar<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Herceptin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">HIV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Roche<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Stemline<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biosimilar<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Herceptin<\/span>","<span class=\"advgb-post-tax-term\">HIV<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">Roche<\/span>","<span class=\"advgb-post-tax-term\">Stemline<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Mar 12, 2019","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Mar 12, 2019 2:41 pm","modified":"Updated on Jun 14, 2023 4:22 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4412","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4412"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4412\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4418"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4412"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4412"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4412"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4412"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}